Five-Year Outcomes After Prostatectomy or Radiotherapy for Prostate Cancer: The Prostate Cancer Outcomes Study

Potosky, Arnold L.; Davis, William W.; Hoffman, Richard M.; Stanford, Janet L.; Stephenson, Robert A.; Penson, David F.; Harlan, Linda C.

doi:10.1093/jnci/djh259

Cited by 575 publications

(455 citation statements)

References 37 publications

Supporting

Mentioning

416

Contrasting

Unclassified

Order By: Relevance

“…Studies as well as review articles on this topic that summarize research to date are available in this and other publications. 1,3,5,6,8,9,[11][12][13][14] In spite of the advances toward the restoration of erectile functioning promoted by nerve-sparing surgery, [15][16][17][18] penile rehabilitation 16,[19][20][21][22] and erectogenic aids, 3,11,[23][24][25] satisfaction with erectile dysfunction treatment appears to vary with the particular treatment, and is typically reported not to be high by the men who sought help. 13,26,27 Miller et al 28 reported that only 10% of men were satisfied with their treatments.…”

Section: Resultsmentioning

confidence: 99%

The psychosocial aspects of sexual recovery after prostate cancer treatment

et al. 2009

View full text Add to dashboard Cite

Prostate cancer affects one in six American men. Erectile and sexual dysfunctions are long-term side effects of prostate cancer treatment. PubMed database was searched for papers on prostate cancer-related sexual recovery for men and couples. The search yielded articles on (1) the treatment of erectile dysfunction, (2) men's psychological and culturally diverse adaptation to the sexual side effects; (3) the impact of prostate cancer on couples' relationships; and (4) interventions to promote sexual function. Erectile dysfunction after prostate cancer treatment has been widely studied.Research on the sexual recovery of men and couples or understanding it in a cultural context is scarce. Greater focus on the impact of sexual sequelae of prostate cancer treatment on men as well as couples in diverse groups is needed. Clinical implications for treating sexual dysfunction and promoting sexual recovery for prostate cancer survivors and their partners are discussed. Recommendations for future research are provided.

show abstract

Section: Resultsmentioning

confidence: 99%

The psychosocial aspects of sexual recovery after prostate cancer treatment

et al. 2009

View full text Add to dashboard Cite

show abstract

“…The eventual UCLA-PCI questionnaire consisted of 20 items with questions about both function and bother of urinary, bowel, and sexual function [4,5]. Other multi-center studies have used the UCLA-PCI disease specific measurement scale in addition to a variety of general health scales to analyze the side effects of prostate cancer treatments [6][7][8]. The UCLA-PCI has been modified to address specific questions.…”

Section: Validated Questionnaires: Instruments To Measure Hrqolmentioning

confidence: 99%

Measuring Health-Related Quality of Life Consequences From Primary Treatment for Early-Stage Prostate Cancer

Dandapani

Sanda

2008

Seminars in Radiation Oncology

View full text Add to dashboard Cite

“…In addition to initial treatment cost differences, prostate cancer therapies can have important short-term and long-term sequelae requiring various amounts of additional treatment. 5 Some treatments rely on outpatient care, whereas others require inpatient services. Because of differences in insurance coverage, the setting in which care is delivered may have important economic implications.…”

mentioning

confidence: 99%

How does initial treatment choice affect short‐term and long‐term costs for clinically localized prostate cancer?

Snyder

Frick

Blackford³

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND. Data regarding costs of prostate cancer treatment are scarce. This study investigates how initial treatment choice affects short-term and long-term costs. METHODS. This retrospective, longitudinal cohort study followed prostate-cancer cases diagnosed in 2000 for 5 years using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Men age !66 years, in Medicare fee for service, diagnosed with clinically localized prostate cancer in 2000 while residing in a SEER region, were matched to noncancer controls using age, sex, race, region, comorbidity, and survival. On the basis of treatment received during the first 9 months postdiagnosis, patients were assigned to watchful waiting, radiation, hormonal therapy, hormonal þ radiation, and surgery (may have received other treatments). Incremental costs for prostate cancer were the difference in costs for prostate cancer cases versus matched controls. Costs were divided into initial treatment (months À1 to 12), long-term (each 12 months thereafter), and total (months À1 to 60). Sensitivity analyses excluded the last 12 months of life. RESULTS. A total of 13,769 prostate-cancer cases were matched to 13,769 noncancer controls. Watchful waiting had the lowest initial treatment ($4270) and 5-year total costs ($9130). Initial treatment costs were highest for hormonal þ radiation ($17,474) and surgery ($15,197). At $26,896, 5-year total costs were highest for hormonal therapy only followed by hormonal þ radiation ($25,097) and surgery ($19,214). After excluding the last 12 months of life, total costs were highest for hormonal þ radiation ($23,488) and hormonal therapy ($23,199). CONCLUSIONS. Patterns of costs vary widely based on initial treatment. These data can inform patients and clinicians considering treatment options and policy makers interested in patterns of costs. Cancer 2010;116:5391-9.

show abstract

Five-Year Outcomes After Prostatectomy or Radiotherapy for Prostate Cancer: The Prostate Cancer Outcomes Study

Cited by 575 publications

References 37 publications

The psychosocial aspects of sexual recovery after prostate cancer treatment

The psychosocial aspects of sexual recovery after prostate cancer treatment

Measuring Health-Related Quality of Life Consequences From Primary Treatment for Early-Stage Prostate Cancer

How does initial treatment choice affect short‐term and long‐term costs for clinically localized prostate cancer?

Contact Info

Product

Resources

About